
Scribe Therapeutics to Collaborate With Biogen to Develop CRISPR-based Genetic Medicines for Neurological Diseases Including ALS
|
October 6, 2020
X min read
Scribe Therapeutics to collaborate with Biogen to develop CRISPR-based genetic medicines for neurological diseases, including ALS
|
October 6, 2020
Share on Social
More like this
Media
Scribe Therapeutics to Participate in Upcoming Healthcare Investor Conferences
November 5, 2026
Read Now
Press
Scribe Therapeutics to Participate in Upcoming Healthcare Investor Conferences
November 5, 2026
Read Now
Media
Scribe Therapeutics to Present Updated Data on PCSK9-Targeting Epigenetic Silencing and LPA-Targeting Gene Editing Programs at American Heart Association (AHA) Scientific Sessions 2026
November 4, 2026
Read Now
Press
Scribe Therapeutics to Present Updated Data on PCSK9-Targeting Epigenetic Silencing and LPA-Targeting Gene Editing Programs at American Heart Association (AHA) Scientific Sessions 2026
November 4, 2026
Read Now